Related Experiment Video

Updated: May 29, 2026

Rapid Detection of Bacterial Pathogens Causing Lower Respiratory Tract Infections via Microfluidic-Chip-Based Loop-Mediated Isothermal Amplification
06:11

Rapid Detection of Bacterial Pathogens Causing Lower Respiratory Tract Infections via Microfluidic-Chip-Based Loop-Mediated Isothermal Amplification

Published on: March 29, 2024

Biomarkers to optimize antibiotic therapy for pneumonia due to multidrug-resistant pathogens

Charles-Edouard Luyt1, Alain Combes, Jean-Louis Trouillet

  • 1Service de Réanimation Médicale, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, France. charles-edouard.luyt@psl.aphp.fr

Clinics in Chest Medicine
|August 27, 2011
PubMed

Insights

No diagnostic biomarker exists for multidrug-resistant ventilator-associated pneumonia. Procalcitonin levels can guide antimicrobial therapy duration, reducing patient harm when concentrations fall below 0.5 ng/mL or decrease by 80%.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Clinical Diagnostics

Background:

  • Ventilator-associated pneumonia (VAP) caused by multidrug-resistant pathogens presents a significant clinical challenge.
  • Currently, no specific diagnostic biomarker reliably identifies VAP caused by these resistant organisms.

Purpose of the Study:

  • To evaluate the utility of procalcitonin in managing antimicrobial therapy for VAP.
  • To determine if procalcitonin can guide the discontinuation of antibiotics without increasing patient morbidity and mortality.

Main Methods:

  • The study likely involved monitoring procalcitonin levels in patients with VAP.
  • Antibiotic treatment duration was adjusted based on predefined procalcitonin concentration thresholds or percentage decrease from peak levels.

Main Results:

  • Procalcitonin monitoring allows for customized antimicrobial treatment duration.
  • Stopping antibiotics when procalcitonin is <0.5 ng/mL or decreases by ≥80% did not result in excess morbidity and mortality.
  • Close post-treatment surveillance is necessary to detect potential infection recurrence.

Conclusions:

  • Procalcitonin serves as a valuable biomarker for guiding antimicrobial stewardship in VAP.
  • This strategy enables safe de-escalation of antibiotic therapy, reducing unnecessary exposure.
  • Continued vigilance is crucial after antibiotic cessation to manage VAP effectively.

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...